Literature DB >> 25177051

Follow-up testing for hepatitis C virus infection: an analysis of Massachusetts surveillance data, 2007-2010.

Kerri Barton1, Dan Church1, Shauna Onofrey1, Noelle Cocoros1, Alfred DeMaria1.   

Abstract

The Massachusetts Department of Public Health (MDPH) identified cases of hepatitis C virus (HCV) infection reported from 2007 through 2010 to assess evidence of appropriate follow-up testing for the diagnosis of active HCV infection. Surveillance data were used to assess the number of people with reported HCV who had an antibody test and nucleic acid test (NAT) for HCV, to determine the time between tests, and to identify demographic characteristics. Out of the 34,005 cases of HCV reported with laboratory results during the study period, 45% (n=15,279) had only an antibody test reported and 55% (n=18,726) had a NAT reported, with differences by age, gender, and region of residence. Nearly half of those with reported cases of HCV infection in Massachusetts did not have a NAT reported to MDPH, indicating that these individuals may not have received appropriate diagnostic testing. Analysis of demographics suggests differences by age, gender, and region.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25177051      PMCID: PMC4116367          DOI: 10.1177/003335491412900503

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  11 in total

1.  Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms.

Authors:  Steven H Kleinman; Susan L Stramer; Jaye P Brodsky; Sally Caglioti; Michael P Busch
Journal:  Transfusion       Date:  2006-05       Impact factor: 3.157

2.  Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study.

Authors:  Mei-Hsuan Lee; Hwai-I Yang; Sheng-Nan Lu; Chin-Lan Jen; San-Lin You; Li-Yu Wang; Chih-Hao Wang; Wei J Chen; Chien-Jen Chen
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

Review 3.  Hepatitis C virus infection in USA: an estimate of true prevalence.

Authors:  Eric Chak; Andrew H Talal; Kenneth E Sherman; Eugene R Schiff; Sammy Saab
Journal:  Liver Int       Date:  2011-03-16       Impact factor: 5.828

Review 4.  Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.

Authors:  Kyle John Wilby; Nilufar Partovi; Jo-Ann E Ford; Erica Greanya; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2012-04       Impact factor: 3.522

5.  The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

Authors:  Kathleen N Ly; Jian Xing; R Monina Klevens; Ruth B Jiles; John W Ward; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2012-02-21       Impact factor: 25.391

6.  New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.

Authors:  Shan Liu; Lauren E Cipriano; Mark Holodniy; Douglas K Owens; Jeremy D Goldhaber-Fiebert
Journal:  Ann Intern Med       Date:  2012-02-21       Impact factor: 25.391

7.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

Review 8.  Current status and future directions in the management of chronic hepatitis C.

Authors:  Wosen Aman; Shaymaa Mousa; Gamal Shiha; Shaker A Mousa
Journal:  Virol J       Date:  2012-03-02       Impact factor: 4.099

9.  Vital signs: evaluation of hepatitis C virus infection testing and reporting - eight U.S. sites, 2005-2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-05-10       Impact factor: 17.586

10.  Testing for HCV infection: an update of guidance for clinicians and laboratorians.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-05-10       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.